Dr RR Baliga's "Got Knowledge Doc" Podkast

Delighted to share a concise update on the latest NEJM review of Long QT Syndrome 🫀📘 — a masterful synthesis by Schwartz & Crotti that reframes how we recognize risk, personalize therapy, and prevent sudden death in this genetically mediated disorder. The piece highlights ion-channel biology, gene-specific triggers, the impact of modifier genes, and the effectiveness of a tiered therapeutic approach including beta-blockers, mexiletine, and left cardiac sympathetic denervation ⚡️🧬🛡️.

For clinicians and trainees, it's a compelling reminder that precise diagnosis, careful QT interpretation, and yearly risk reassessment remain central to saving lives. Highly recommended reading for anyone involved in cardiac electrophysiology or inherited arrhythmia care 📚✨

🧠✨ Leibniz: Harmony, Logic, and the Birth of the Digital Mind

Celebrating Gottfried Wilhelm Leibniz — the mathematician-philosopher who co-created calculus, invented binary arithmetic, and envisioned a world stitched together by pre-established harmony. His Monadology reads like proto-systems theory, and his binary system is the quiet ancestor of every computer we use today.

For clinicians and scientists, his legacy whispers:

🔹 Seek the sufficient reason behind every pattern

🔹 Value multiple perspectives — every "monad" reflects a different truth

🔹 Build harmonies across disciplines, data streams, and patient narratives

🧩💡 From metaphysics to modern computing, he reminds us that insight deepens when logic meets wonder.

🧬 New insights into autism: A 2025 JCI Viewpoint highlights how hundreds of genes, polygenic risk, and specific environmental factors converge during fetal brain development to shape autism likelihood.

🧠 Early biomarkers—from infant MRI and ERPs to machine-learning models using EHR data—are accelerating earlier, more tailored interventions.

🌱 Advances in gene therapy, IGF-1 pathways, and proteomics offer emerging therapeutic possibilities.

🤝 Centering autistic voices remains essential as precision approaches evolve.

🔍 Peripheral Neuropathy: What Clinicians Should Know 🧠⚡

Peripheral neuropathy affects ~1% of adults worldwide, with diabetes accounting for more than half of all cases. The JAMA review highlights why length-dependent patterns dominate, how metabolic stress injures long axons first, and why sensory symptoms outpace motor loss. Evidence-based evaluation still begins with glucose testing, vitamin B12 with methylmalonic acid, and serum protein electrophoresis.

First-line therapies for neuropathic pain — gabapentin, pregabalin, duloxetine, and tricyclics — offer meaningful but often incomplete relief, reminding us that prevention and risk factor modification remain central.

A clear, elegant synthesis of mechanisms, diagnostics, and management — essential reading for anyone caring for patients with numbness, tingling, or burning feet. 👣✨

New NEJM insights on asymptomatic carotid stenosis 🧠🔍

The CREST-2 trials offer a landmark update: intensive medical therapy remains the cornerstone, while carotid stenting shows selective benefit when performed by expert operators. Endarterectomy, however, provides no significant advantage over modern medical management.

With stricter blood-pressure and LDL targets, plus expanding use of PCSK9 inhibitors, the future of stroke prevention is increasingly precision-driven, medically optimized, and patient-centered. 💊📉✨

A thoughtful read for all involved in vascular care, cerebrovascular prevention, and clinical decision-making. 📘🫀

The new Lancet Series on ultra-processed foods offers a striking insight: as UPFs rise globally, traditional whole-food diets decline—bringing nutrient imbalance, overeating, toxic exposures, and hyper-palatable formulations that quietly reshape health trajectories. 🍔➡️⚠️

Across more than 100 prospective studies and multiple trials, higher UPF intake consistently links to obesity, type 2 diabetes, cardiovascular disease, kidney disease, depression, and higher all-cause mortality. 📉🩺

The message is clear: reducing UPF consumption isn't a wellness trend—it's a public health imperative. Evidence-based policies and renewed investment in minimally processed, culturally rooted food systems are urgently needed. 🌱🔬🌏

#UltraProcessedFoods #PublicHealth #Nutrition #ChronicDisease #LancetSeries

Home-delivered DASH-patterned groceries paired with dietitian counseling meaningfully lowered blood pressure and LDL cholesterol among Black adults living in food deserts 🥗📉—as demonstrated in the GoFresh randomized trial (JAMA).

An accompanying editorial highlights why future "food-as-medicine" programs must prioritize underconsumed, health-promoting foods and align with modern evidence favoring higher-fat DASH/Mediterranean patterns 🌱🫒.

A powerful reminder: the right groceries can be therapeutic.

🩺 New insights in hemodialysis care.

A major New England Journal of Medicine study reports that daily supplementation with long-chain omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) led to a 43% reduction in serious cardiovascular events among adults receiving maintenance hemodialysis. 🐟💙

In a population where traditional cardioprotective therapies often fall short, these findings open a fresh path for investigation — and perhaps, future practice. 📉🔬

A confirmatory trial will be essential, but the signal is compelling. 🌅

🚀 A milestone moment in lipid therapeutics!

The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy.

For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊

Safety was comparable to placebo, and effects were rapid, robust, and sustained to 52 weeks. The ongoing CORALreef Outcomes trial will determine its impact on major cardiovascular events. 🔬❤️

Innovation in lipid lowering is accelerating—and patient-centered options are expanding.

#JAMA #LipidManagement #HeFH #CardiovascularHealth #PCSK9 #Enlicitide #Prevention 🌟

☕ DECAF Trial insight!

A new JAMA study shows that daily caffeinated coffee may lower recurrence of atrial fibrillation compared with abstinence.

Patients drinking ~1 cup/day had 47% recurrence vs 64% with abstinence (HR 0.61, p=0.01) 📉💓

No major safety concerns—challenging long-held beliefs that coffee is proarrhythmic.

💡Takeaway: For many patients with AF, enjoying their morning brew may be both safe and possibly beneficial.

#AtrialFibrillation #Cardiology #JAMA #ClinicalTrials #HeartHealth ☕💓📊